Close Menu

NEW YORK – The last few years have been challenging ones for the nursing home testing business, as downward pressures on reimbursement and the Protecting Access to Medicare Act (PAMA) have trimmed test margins.

The ongoing SARS-CoV-2 pandemic has added to the space's difficulties as labs focused on nursing home testing have seen the same declines in routine testing that have impacted the rest of the industry but have not, in many cases, benefited from rising SARS-CoV-2 test volumes.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.